Chapter 6: Diseases of the Immune System Flashcards

1
Q

List different mechanisms of hypersensitivity reactions and prototypical disorders.

A
  • Immediate (type I) hypersensitivity: anaphylaxis; allergies; bronchial asthma (atopic forms)
  • Antibody-mediated (type II) hypersensitivity: autoimmune hemolytic anemia; Goodpasture syndrome
  • Immune complex–mediated (type III) hypersensitivity: systemic lupus erythematosus; some forms of glomerulonephritis; serum sickness; Arthus reaction
  • Cell-mediated (type IV) hypersensitivity: contact dermatitis; multiple sclerosis; type 1 diabetes; tuberculosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List 1997 Revised Criteria for Classification of Systemic Lupus Erythematosus.

A

Clinical Criteria
* Acute cutaneous lupus: malar rash, photosensitivity (cutaneous lupus)
* Chronic cutaneous lupus: discoid rash (cutaneous lupus)
* Nonscarring alopecia in the absence of other causes
* Oral or nasal ulcers
* Joint disease: nonerosive synovitis involving two or more peripheral joints
* Serositis: pleuritis, pericarditis
* Renal disorder: persistent proteinuria >0.5g/24 hours, or red cell casts
* Neurologic disorder: seizures, psychosis, myelitis, or neuropathy, in the absence of offending drugs or other known causes
* Hemolytic anemia (cytopenia)
* Leukopenia or lymphopenia on two or more occasions (cytopenia)
* Thrombocytopenia in the absence of offending drugs and other conditions (cytopenia)

Immunologic Criteria
* Antinuclear antibody (ANA)
* Anti-dsDNA antibody
* Anti-Sm antibody
* Antiphospholipid antibody
* Low complement (C3, C4, or CH50)
* Direct Coombs test in the absence of clinically evident hemolytic anemia

NB: 4 of 17 criteria, including at least 1 clinical criterion and 1 immunologic criterion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Most sensitive antibody in SLE?

A

ANA (95-100%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antibody(ies) specific for SLE?

A
  • Anti-double-stranded DNA (anti-dsDNA)
  • Anti-Smith (anti-Sm)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Antibody(ies) specific for systemic sclerosis?

A
  • Antitopoisomerase 1 (anti-Scl-70)
  • Anticentromere antibody associated with CREST syndrome

TOPOgraphical map: at large = systemic sclerosis
Centromere: Crest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Antibody(ies) specific for Sjögren syndrome?

A
  • Anti-Ro/SS-A
  • Anti-La/SS-B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Antibody(ies) specific for rheumatoid arthritis?

A
  • Anti-CCP

CCP: Common Cold calls for Painkillers (rhume)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mechanisms of tissue injury in SLE?

A
  • Most of the systemic lesions are caused by immune complexes (type III hypersensitivity). DNA–anti-DNA complexes can be detected in the glomeruli and small blood vessels in animal models. Low levels of serum complement (secondary to consumption of complement proteins) and granular deposits of complement and immunoglobulins in the glomeruli further support the role of immune complex deposition. An acute necrotizing vasculitis involving capillaries, arterioles, and small arteries may be present in any tissue.
  • Autoantibodies specific for red blood cells, white blood cells, and platelets opsonize these cells and promote their phagocytosis and destruction, resulting in cytopenias. These are examples of antibody-mediated (type II) hypersensitivity.
  • Antiphospholipid antibody syndrome. Patients with antiphospholipid antibodies may develop venous and arterial thromboses, which may be associated with recurrent spontaneous miscarriages and focal cerebral or ocular ischemia.
  • The neuropsychiatric manifestations of SLE have been attributed to antibodies that cross the blood-brain barrier and react with neurons or receptors for various neurotransmitters. Other immune factors, such as cytokines, may also be involved in the cognitive dysfunction and CNS abnormalities that are associated with SLE.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

6 patterns of glomerular disease seen in SLE..?

A
  • Minimal mesangial lupus nephritis (class I) is the least common and is characterized by immune complex deposition in the mesangium, identified by immunofluorescence and by electron microscopy, but without structural changes by light microscopy.
  • Mesangial proliferative lupus nephritis (class II) is characterized by mesangial cell proliferation, often accompanied by accumulation of mesangial matrix, and granular mesangial deposits of immunoglobulin and complement without involvement of glomerular capillaries.
  • Focal lupus nephritis (class III) is defined by involvement of fewer than 50% of glomeruli. The lesions may be segmental (affecting only a portion of the glomerulus) or global (involving the entire glomerulus). Affected glomeruli may exhibit swelling and proliferation of endothelial and mesangial cells, leukocyte accumulation, capillary necrosis, and hyaline thrombi. There is also often extracapillary proliferation associated with focal necrosis and crescent formation. The clinical presentation ranges from mild hematuria and proteinuria to acute renal insufficiency. Red blood cell casts in the urine are common when the disease is active. Some patients progress to diffuse glomerulonephritis. The active (or proliferative) inflammatory lesions can heal completely or lead to chronic global or segmental glomerular scarring.
  • Diffuse lupus nephritis (class IV) is the most common and severe form of lupus nephritis. The lesions are similar to those in class III, but differ in extent; typically, in class IV nephritis half or more of the glomeruli are affected. As in class III, the lesions may be segmental or global and on the basis of this, it can be subclassified as Class IV segmental (IV-S) or Class IV global (IV-G). Involved glomeruli show proliferation of endothelial, mesangial, and epithelial cells, with the latter producing cellular crescents that fill Bowman’s space. Subendothelial immune complex deposits may cause circumferential thickening of the capillary wall, forming “wire loop” structures on light microscopy. Immune complexes can be readily detected by electron microscopy and immunofluorescence. Lesions may progress to scarring of glomeruli. Patients with diffuse glomerulonephritis are usually symptomatic, showing hematuria as well as proteinuria. Hypertension and mild to severe renal insufficiency are also common.
  • Membranous lupus nephritis (class V) is characterized by diffuse thickening of the capillary walls due to deposition of subepithelial immune complexes, similar to idiopathic membranous nephropathy. The immune complexes are usually accompanied by increased production of basement membrane–like material. This lesion typically causes severe proteinuria or nephrotic syndrome and may occur concurrently with focal or diffuse lupus nephritis.
  • Advanced sclerosing lupus nephritis (class VI) is characterized by sclerosis of more than 90% of the glomeruli and represents end-stage renal disease.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Distinguish chronic discoid lupus erythematosus from SLE.

A
  • Skin manifestations mimicking SLE, but without the systemic manifestations (or only rarely)
  • 35% ANA (+)
  • Anti-dsDNA (-)
  • IF similar to SLE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Distinguish drug-induced lupus erythematosus from SLE.

A
  • Drug-induced: hydralazine, procainamide, isoniazid, and d-penicillamine, anti-TNF therapy, to name only a few
  • Most associated with development of ANAs
  • Variable SLE-like syndrome including arthralgias, fever, and serositis
  • Renal and CNS involvement is distinctly uncommon
  • Antibodies specific for double-stranded DNA are rare, but there is an extremely high frequency of antibodies specific for histones
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Distinguish subacute cutaneous lupus erythematosus from chronic discoid lupus erythematosus.

A
  • The skin rash tends to be widespread, superficial, and nonscarring
  • Most patients have mild systemic symptoms consistent with SLE
  • Strong association with antibodies to the SS-A antigen and with the HLA-DR3 genotype
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Characteristic clinical features of Sjögren syndrome?

A
  • Dry eyes (keratoconjunctivitis sicca)
  • Dry mouth (xerostomia)
  • About 5% of Sjögren patients develop marginal zone lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Most common disorders associated with secondary Sjögren syndrome?

A
  • Rheumatoid arthritis (most common)
  • SLE
  • Polymyositis
  • Scleroderma
  • Vasculitis
  • Mixed connective tissue disease
  • Thyroiditis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sjögren syndrome: histologic findings (salivary glands)?

A
  • Periductal and perivascular lymphocytic infiltration (early)
  • Lymphoid follicles with germinal centers
  • Ductal epithelial cell hyperplasia with duct obstruction
  • Parenchymal acinar atrophy and hyaline fibrosis
  • Fat replacement (late)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Main organ systems involved in systemic sclerosis?

A
  • Skin (most common)
  • Gastrointestinal tract (intestinal malabsorption)
  • Kidneys (renal failure)
  • Heart (cardiac failure)
  • Muscles
  • Lungs (pulmonary insufficiency)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Distinguish 2 types of systemic sclerosis.

A
  • Diffuse scleroderma: widespread skin involvement at onset, with rapid progression and early visceral involvement
  • Limited scleroderma: relatively benign clinical course where skin involvement is confined to fingers, forearms, and face, and visceral involvement occurs late
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Define CREST syndrome.

A

Some patents with limited scleroderma develop a combination of Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Histology of skin lesions in systemic sclerosis?

A
  • Perivascular infiltrates containing CD4+ T cells and edema
  • Degeneration of collagen fibers, which become eosinophilic
  • Capillaries and small arteries may show thickening of the basal lamina (progressing to hyaline thickening of their walls), endothelial cell damage, and partial occlusion
  • Increasing fibrosis of the dermis
  • Atrophy of the epidermis and dermal appendages
  • Focal and sometimes diffuse subcutaneous calcifications, especially in patients with the CREST syndrome
  • Ulceration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

The term mixed connective tissue disease is used to describe a disease with clinical features that overlap with those of..?

A
  • SLE
  • Systemic sclerosis
  • Polymyositis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Mixed connective tissue disease is characterized serologically by..?

A

…high titers of antibodies to U1 ribonucleoprotein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Clinical features of mixed connective tissue disease?

A
  • Synovitis of the fingers
  • Raynaud phenomenon
  • Myositis
  • Renal involvement

NB: …which is modest and responds well to corticosteroids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Examples of IgG4-related disease?

A
  • Mikulicz syndrome (lacrimal gland, parotid gland, and submandibular gland)
  • Küttner tumor (bilateral submandibular gland)
  • Riedel thyroiditis (thyroid)
  • Idiopathic retroperitoneal fibrosis
  • Autoimmune pancreatitis
  • Inflammatory pseudotumors of the orbit, lungs, and kidneys
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

List 3 classes of graft rejection.

A
  • Hyperacute
  • Acute
  • Chronic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe the immune response occurring in hyperacute rejection.

A

Mediated by preformed antibodies specific for antigens on graft endothelial cells (natural IgM antibodies specific for blood group antigens, or antibodies specific for allogeneic MHC molecules that were induced by prior exposure of the organ recipient to allogeneic cells). Immediately after the graft is implanted and blood flow is restored, the antibodies bind to antigens on the graft vascular endothelium and activate the complement system.

26
Q

Describe the immune response occurring in acute cellular rejection.

A

CD8+ CTLs may directly destroy graft cells, or CD4+ cells secrete cytokines and induce inflammation, which damages the graft. T cells may also react against graft vessels, leading to vascular damage.

27
Q

Describe the immune response occurring in acute antibody-mediated rejection.

A

Antibodies bind to vascular endothelium and activate complement via the classical pathway.

28
Q

Describe the immune response occurring in chronic rejection.

A
  • T cells that react against graft alloantigens and secrete cytokines, which stimulate the proliferation and activities of fibroblasts and vascular smooth muscle cells in the graft
  • Alloantibodies also contribute to chronic rejection
29
Q

Clinical presentation of hyperacute rejection?

A

Immediately after the graft is implanted and blood flow is restored, antidonor antibodies bind to antigens on the graft vascular endothelium and activate the complement system, leading to endothelial injury, thrombosis, and ischemic necrosis of the graft. Hyperacute rejection is rare because every donor and recipient are matched for blood type, and potential recipients are tested for antibodies against the cells of the prospective donor, a test called a cross-match.

30
Q

Clinical presentation (temporality) of chronic rejection?

A

An indolent form of graft damage that occurs over months or years, leading to progressive loss of graft function.

31
Q

Clinical presentation (temporality) of acute rejection?

A
  • Occurs within days or weeks after transplantation and is the principal cause of early graft failure
  • May also appear suddenly much later after transplantation if immunosuppression is tapered or terminated

NB: The recognition of cellular rejection is important because, in the absence of accompanying humoral rejection, most patients respond well to immunosuppressive therapy.

32
Q

Histology of hyperacute rejection of a kidney transplant?

A
  • Virtually all arterioles and arteries exhibit acute fibrinoid necrosis of their walls
  • Narrowing or complete occlusion of their lumens by thrombi
  • Neutrophils rapidly accumulate within arterioles, glomeruli, and peritubular capillaries
  • Thrombotic occlusion of glomerular capillaries leading to cortical necrosis (infarction)
33
Q

Histology of acute cellular rejection of a kidney transplant?

A
  • Tubulointerstitial pattern (type I): extensive interstitial inflammation and tubular inflammation (tubulitis) associated with focal tubular injury, where the inflammatory infiltrate is dominated by CD4+ and CD8+ T lymphocytes
  • Vascular pattern: inflammation of vessels (type II) including swollen endothelial cells and endothelialitis/endarteritis/intimal arteritis (lymphocytes between the endothelium and the vessel wall), and sometimes necrosis of vessel walls (type III)
34
Q

Histology of acute antibody-mediated rejection of a kidney transplant?

A
  • Damage to glomeruli: inflammation of glomeruli
  • Damage to small blood vessels: inflammation of peritubular capillaries (capillaritis)
  • Small vessels also may show focal thrombosis
35
Q

Histology of chronic rejection of a kidney transplant?

A
  • Dominated by vascular changes, often with intimal thickening and vascular occlusion
  • Glomerulopathy, with duplication of the basement membrane, likely secondary to chronic endothelial injury
  • Peritubular capillaritis with multilayering of peritubular capillary basement membranes
  • Interstitial fibrosis and tubular atrophy (IFTA) with loss of renal parenchyma may occur secondary to the vascular lesions
  • Sparse interstitial mononuclear cell infiltrates
36
Q

Consequences of immunosuppression?

A
  • Increased susceptibility to opportunistic infections
  • One of the most frequent infectious complications is reactivation of polyoma virus (infects renal tubules, and may even cause graft failure)
  • EBV-induced lymphomas
  • Human papillomavirus–induced squamous cell carcinomas
  • Kaposi sarcoma
37
Q

Two problems that are unique to HSC transplantation?

A
  • Graft-versus-host disease (GVHD)
  • Immunodeficiency
38
Q

Clinical features of acute GVHD?

A
  • Occurs within days to weeks after allogeneic HSC transplantation
  • The major clinical manifestations result from involvement of the immune system and epithelia of the skin, liver, and intestines
  • Skin: a generalized rash that may lead to desquamation in severe cases
  • Liver: destruction of small bile ducts gives rise to jaundice
  • GI: mucosal ulceration of the gut results in bloody diarrhea
  • The affected tissues are usually not heavily infiltrated by lymphocytes
39
Q

Clinical features of chronic GVHD?

A
  • Following acute GVHD vs insidious onset
  • Skin: extensive cutaneous injury, with destruction of skin appendages and fibrosis of the dermis
  • Liver: chronic liver disease manifested by cholestatic jaundice
  • GI: damage to the gastrointestinal tract may cause esophageal strictures
  • Immune system: the immune system is devastated, with involution of the thymus and depletion of lymphocytes in the lymph nodes –> recurrent and life-threatening infections and manifestations of autoimmunity
40
Q

Pathophysiology of GVHD?

A
  • The immunocompetent T cells present in the donor inoculum recognize the recipient’s HLA antigens as foreign and react against them
  • Direct cytotoxicity by CD8+ T cells
  • Cytokines released by the sensitized donor T cells
  • Re: autoimmunity arising with chronic GVHD: postulated to result from the grafted CD4+ helper T cells reacting with host B cells and stimulating these cells, some of which may be capable of producing autoantibodies
41
Q

Main infectious complication of HSC transplantation?

A

CMV, where CMV-induced pneumonitis can be a fatal complication.

42
Q

2 main categories of defects in innate immunity with one example for each?

A
  • Defects in leukocyte function: Chédiak-Higashi syndrome (decreased leukocyte functions because of mutations affecting protein involved in lysosomal membrane traffic)
  • Defects in the complement system: C3 deficiency (defects in all complement functions)
43
Q

List examples of defects in adaptive immunity.

A
  • Severe combined immunodeficiency (SCID)
  • X-linked agammaglobulinemia
  • DiGeorge syndrome (thymic hypoplasia)
  • Hyper-IgM syndrome
  • Common variable immunodeficiency
  • Isolated IgA deficiency
  • X-linked lymphoproliferative disease
44
Q

2 prototypical examples of immunodeficiencies associated with systemic diseases?

A
  • Wiskott-Aldrich syndrome
  • Ataxia telangiectasia
45
Q

Molecular pathogenesis, pattern of inheritance and main clinical features of Wiskott-Aldrich syndrome?

A
  • Mutations in the gene (WAS) located at Xp11.23 that encodes Wiskott-Aldrich syndrome protein (WASP) which belongs to a family of proteins that are believed to link membrane receptors, such as antigen receptors, to cytoskeletal elements
  • X-linked
  • Thrombocytopenia
  • Eczema
  • Immunodeficiency: marked vulnerability to recurrent infection
46
Q

Molecular pathogenesis, pattern of inheritance and main clinical features of ataxia telangiectasia?

A
  • Germline inactivation of ataxia-telangiectasia-mutated (ATM) gene on chromosome 11, which encodes for a serine/threonine protein kinase (ATM) involved in DNA repair secondary to double-strand DNA breaks and stabilization of double-strand DNA break complexes during V(D)J recombination –> may impair the generation of antigen receptors and interfere with the process of Ig isotype switching
  • Autosomal-recessive
  • Abnormal gait (ataxia)
  • Vascular malformations (telangiectases)
  • Neurologic deficits
  • Increased incidence of tumors
  • Immunodeficiency: upper and lower respiratory tract bacterial infections, and multiple autoimmune phenomena
47
Q

Causes of secondary (acquired) immunodeficiencies and their respective mechanisms?

A
  • Human immunodeficiency virus infection: depletion of CD4+ helper T cells
  • Irradiation and chemotherapy treatments for cancer: decreased bone marrow precursors for all leukocytes
  • Involvement of bone marrow by cancers (metastases, leukemias): reduced site of leukocyte development
  • Protein-calorie malnutrition: metabolic derangements inhibit lymphocyte maturation and function
  • Removal of spleen: decreased phagocytosis of microbes
48
Q

Five groups of adults at high risk for developing AIDS?

A
  • Men who have sex with men
  • Heterosexual transmission, chiefly due to contact with members of other high-risk groups (e.g., intravenous drug users)
  • Intravenous drug users with no previous history of homosexuality are the next largest group
  • HIV infection of the newborn: children of HIV-positive women are at risk for infection in utero, at birth, or through breast milk
  • Patients with hemophilia, especially those who received large amounts of factor VIII or factor IX concentrates before 1985
  • Recipients of blood and blood components who are not hemophiliacs but who received transfusions of HIV-infected whole blood or components (e.g., platelets, plasma)
49
Q

What type of virus is HIV?

A

HIV is a nontransforming human retrovirus belonging to the lentivirus family

50
Q

What main type of immune deficiency characterizes AIDS?

A

Cell-mediated immunity (CD4+ helper T cells)

51
Q

What cell type is infected by the virus in HIV-associated neurocognitive disorder (HAND)?

A

Microglia

52
Q

Define the different clinical categories of HIV infections.

A

A.Asymptomatic, acute (primary) HIV, or persistent generalized lymphadenopathy
1. ≥500 cells/µL (CD4+ T cells)
2. 200-499 cells/µL
3. <200 cells/µL

B.Symptomatic, not A or C conditions
1. ≥500 cells/µL (CD4+ T cells)
2. 200-499 cells/µL
3. <200 cells/µL

C.AIDS indicator conditions: including opportunistic infections, neurologic disease, and tumors

53
Q

List AIDS-Defining Opportunistic Infections and Neoplasms Found in Patients With HIV Infection.

A
54
Q

Describe the general physical nature of amyloid.

A

By electron microscopy, all types of amyloid, regardless of clinical setting or chemical composition, consist of continuous, nonbranching fibrils (fibers) with a diameter of approximately 7.5 to 10 nm. X-ray crystallography and infrared spectroscopy demonstrate a characteristic cross-β-pleated sheet conformation. Each fiber (or fibril) is made up of up to 6 fibrils (or protofilaments).

55
Q

Describe Robbins’ classification scheme for amyloidosis.

A
  • Systemic (Generalized) Amyloidosis, including primary (clonal plasma cell proliferations) and secondary (complication of an underlying chronic inflammatory process) forms
  • Localized Amyloidosis
  • Hereditary Amyloidosis
56
Q

Give and characterize (Associated Diseases, Major Fibril Protein, Chemically Related Precursor Protein) one example of systemic (generalized), primary amyloidosis.

A
  • Clinicopathologic category: Immunoglobulin light chain amyloidosis
  • Associated diseases: Multiple myeloma and other monoclonal plasma cell proliferations
  • Major fibril protein: AL (amyloid light chain protein)
  • Chemically related precursor protein: Immunoglobulin light chains, chiefly λ type

N.B.: Perivascular and vascular deposits are common.

++ Heart, GI tract, resp. tract, peripheral nerves, skin, and tongue

57
Q

Give and characterize (Associated Diseases, Major Fibril Protein, Chemically Related Precursor Protein) one example of systemic (generalized), secondary amyloidosis.

A
  • Clinicopathologic category: Reactive systemic amyloidosis
  • Associated diseases: Chronic inflammatory conditions
  • Major fibril protein: AA (amyloid-associated [or A] protein)
  • Chemically related precursor protein: SAA (serum amyloid-associated) protein

++ Kidneys, liver, spleen, lymph nodes, adrenals, and thyroid

58
Q

Give and characterize (Associated Diseases, Major Fibril Protein, Chemically Related Precursor Protein) 4 examples of localized amyloidosis.

A
  • Clinicopathologic category: Senile cerebral
  • Associated diseases: Alzheimer disease
  • Major fibril protein: Aβ (β-amyloid protein)
  • Chemically related precursor protein: APP (amyloid precursor protein)
    {{ … }}
  • Clinicopathologic category: Medullary carcinoma of thyroid
  • Major fibril protein: A Cal
  • Chemically related precursor protein: Calcitonin
    {{ … }}
  • Clinicopathologic category: Islets of Langerhans
  • Associated diseases: Type 2 diabetes mellitus
  • Major fibril protein: AIAPP (islet amyloid polypeptide)
  • Chemically related precursor protein: Islet amyloid peptide
    {{ … }}
  • Clinicopathologic category: Isolated atrial amyloidosis
  • Major fibril protein: AANF
  • Chemically related precursor protein: Atrial natriuretic factor
59
Q

Give and characterize (Major Fibril Protein, Chemically Related Precursor Protein) 3 examples of hereditary amyloidosis.

A
  • Clinicopathologic category: Familial mediterranean fever
  • Major fibril protein: AA (amyloid-associated protein)
  • Chemically related precursor protein: SAA (serum amyloid-associated) protein
    {{ … }}
  • Clinicopathologic category: Familial amyloidotic neuropathies (several types)
  • Major fibril protein: ATTR
  • Chemically related precursor protein: Transthyretin (TTR)
    {{ … }}
  • Clinicopathologic category: Systemic senile amyloidosis
  • Major fibril protein: ATTR
  • Chemically related precursor protein: Transthyretin (TTR)
60
Q

Which types of amyloid can be identified by specific immunohistochemical staining?

A
  • AA (amyloid-associated [or A] protein)
  • AL (amyloid light chain protein)
  • ATTR